Literature DB >> 464047

Calcium transport in human red blood cells under hypertonic conditions.

G A Plishker, H J Gitelman.   

Abstract

Calcium accumulation in intact human erythrocytes is enhanced by incubation in hypertonic solutions. Hypertonicity produces an increased permeability of the membrane to calcium that is time-dependent and occurs in the presence or absence of calcium. When hypertonically treated cells are incubated for more than 30 min in 300 mosmol/kg solutions the permeability of the membrane to calcium returns to basal values. Oligomycin inhibits the effect of hypertonicity on calcium uptake. The inhibitory action of oligomycin diminishes as the external sodium increases and can only be observed when the external concentration of potassium is at or below 3 mM. Low intracellular sodium and high intracellular potassium concentrations increase the uptake of calcium. It is concluded for human erythrocytes that 1) the increased permeability of the membrane to calcium produced by hypertonicity is a time-dependent, reversible phenomenon and is independent of calcium, 2) the increase in intracellular potassium concentration associated with hypertonic exposure is an important factor contributing to this response, and 3) interactions between calcium and components of the sodium-potassium transport system may account for the enhanced uptake of calcium produced by hypertonicity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 464047     DOI: 10.1152/ajpcell.1979.237.1.C96

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  2 in total

1.  Effect of a 'sickling pulse' on calcium and potassium transport in sickle cell trait red cells.

Authors:  R M Bookchin; V L Lew
Journal:  J Physiol       Date:  1981-03       Impact factor: 5.182

2.  Myotonic muscular dystrophy: defective phospholipid metabolism in the erythrocyte plasma membrane.

Authors:  J E Grey; H J Gitelman; A D Roses
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.